HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
HALO - Halozyme Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$106.00
DETAILS
HIGH:
$130.00
LOW:
$90.00
MEDIAN:
$105.00
CONSENSUS:
$106.00
DOWNSIDE:
2.31%
Stock News
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents, EP 2,797,622 (EP622) and ordered Merck's central European Market Authorization Holder and worldwide packaging and distribution hub MSD BV to refrain from manufacturing, having manufactured, offering, placing on the market and using, or importing or stocking for these purposes, Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The injunction also forbids MSD to facilitate infringement by its affiliates, including by allowing the use of its European Marketing Authorization.
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE® with two additional exclusive targets. "We are pleased to expand our collaboration with argenx, a recognized leader in immunology, building on the successful development of VYVGART Hytrulo," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme.
Halozyme Announces Appointment of Jim Daly to its Board of Directors
SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors.
Why Women-Run Companies Deserve a Place in Your Portfolio
BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.
Halozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High – Here’s Why
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) reached a new 52-week high on Thursday. The stock traded as high as $116.85 and last traded at $112.44, with a volume of 2702748 shares. The stock had previously closed at $115.13. Wall Street Analyst Weigh In A number of brokerages have weighed in on HALO.
Head to Head Review: Halozyme Therapeutics (NASDAQ:HALO) & Co-Diagnostics (NASDAQ:CODX)
Halozyme Therapeutics (NASDAQ: HALO - Get Free Report) and Co-Diagnostics (NASDAQ: CODX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Analyst Ratings This is a breakdown of recent ratings
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. FTNT, ABBNY, EAT and HALO are some such stocks.
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033PR NewswireSAN DIEGO, Sept. 17, 20
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Convertible Notes").
Bank of America Corp DE Makes New $214.50 Million Investment in Halozyme Therapeutics, Inc. $HALO
Bank of America Corp DE purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,740,561 shares of the biopharmaceutical company's stock, valued at approximately $214,504,000. Bank of America Corp DE owned
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the "Convertible Notes").
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
4 Value Stocks to Buy as Oil Surge Fuels Fed Rate Hike Fears
Unlock your portfolio value by investing in high earnings yield stocks like Ternium, Halozyme, POSCO and Talos Energy.
4 Best PEG Value Stocks to Buy Now for Strong Growth & Return
These four PEG value stocks combine discounted valuations with strong growth prospects, offering investors potential opportunities amid market volatility.
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $1.02 Million Position in Halozyme Therapeutics, Inc. $HALO
VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,100 shares of the biopharmaceutical company's stock, valued at approximately $1,025,000. Other large
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,144,800.00 in Stock
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00. Following the sale, the chief executive officer directly owned 767,780 shares of the
Price Targets
Halozyme price target raised to $130 from $115 at H.C. Wainwright
$130.00
(was $110.79)
Mitchell Kapoor
·
H.C. Wainwright
Halozyme price target raised to $95 from $75 at Wells Fargo
$95.00
(was $103.12)
Wells Fargo
Halozyme price target raised to $105 from $93 at Morgan Stanley
$105.00
(was $98.14)
Sean Laaman
·
Morgan Stanley
Leerink upgraded Halozyme to Outperform on growth, market leadership
$110.00
(was $85.76)
Leerink Partners
Halozyme price target raised to $115 from $95 at H.C. Wainwright
$115.00
(was $85.76)
H.C. Wainwright
Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term Potential
$90.00
(was $68.78)
UBS
Halozyme price target lowered to $93 from $96 at Morgan Stanley
$93.00
(was $71.11)
Morgan Stanley
Halozyme price target raised to $95 from $90 at H.C. Wainwright
$95.00
(was $63.86)
Mitchell Kapoor
·
H.C. Wainwright
Halozyme price target raised to $96 from $94 at Morgan Stanley
$96.00
(was $69.57)
Morgan Stanley
Halozyme price target raised to $94 from $78 at Morgan Stanley
$94.00
(was $72.19)
Morgan Stanley
Halozyme price target raised to $75 from $65 at Wells Fargo
$75.00
(was $73.23)
Wells Fargo
Halozyme price target lowered to $75 from $79 at Morgan Stanley
$75.00
(was $75.11)
Morgan Stanley
Halozyme downgraded to Sell from Neutral at Goldman Sachs
$56.00
(was $64.66)
UBS
Goldman Sachs Downgrades Halozyme Therapeutics (HALO) to Sell 'as we approach peak revenue'
$56.00
(was $62.81)
Corinne Jenkins
·
Goldman Sachs
Halozyme price target raised to $92 from $91 at Citizens JMP
$92.00
(was $66.20)
JMP Securities
Halozyme price target lowered to $79 from $80 at Morgan Stanley
$79.00
(was $67.03)
Morgan Stanley
Halozyme upgraded at Leerink on lower-than-feared Part B exposure
$70.00
(was $66.65)
Leerink Partners
Halozyme price target raised to $90 from $85 at H.C. Wainwright
$90.00
(was $74.94)
H.C. Wainwright
Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley
$62.00
(was $66.58)
Sean Laaman
·
Morgan Stanley
Piper Sandler Reiterates Neutral Rating on Halozyme Therapeutics (HALO)
$52.00
(was $46.72)
Joseph Catanzaro
·
Piper Sandler